Page 301 - Remedial Andrology

Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423)

Volume 4 Issue 1 January 2020
Review Article

Brief Review on Sildenafil

Lokesh Masagiri *, GVKS Abhinav and Naga Subrahmanyam S 3
1
2
1 Bachelor of Pharmacy, Department of Pharmacy Practise, Koringa College of Pharmacy (Affiliated to JNTUK), India
2 II/VI Doctor of Pharmacy, Department of Pharmacy Practise, Koringa College of Pharmacy (Affiliated to JNTUK), India
3 Assistant Professor, Department of Pharmacy Practise, Koringa College of Pharmacy (Affiliated to JNTUK), India
*Corresponding Author: Lokesh Masagiri, Bachelor of Pharmacy, Department of Pharmacy Practise, Koringa College of Pharmacy
(Affiliated to JNTUK), Korangi, Kakinada, Andhra Pradesh, India.
Received: December 04, 2019; Published: December 10, 2019
DOI: 10.31080/ASPS.2020.04.brief-review-on-sildenafil

Abstract
The efficiency of sildenafil citrate, an oral agent for the treatment of erectile dysfunction, has been demonstrated in global studies,
this randomised, double blind, placebo controlled, parlled, group, flexible dose study assessed the efficacy and safety of sildenafil
to treat erectile dysfunction in men. Numerous articles have suggested that it improves endothelial function and a possible role in
premature eujactulation or teatment of lower urinary tract symptoms. Drug approval and market development of sildenafil showed
promise as an oral treatment for erectile dysfunction and it was lanced by pfizer as viagra. It is associated with rapid onset of action
with in 14 minutes for some men and an extended duration of action for upto 12 hours.
Keywords: Phosphodiesterase Inhibitors; Safety; Side Effects; Viagra; Erectile Dysfunction

Introduction and 5.0mg tadalafil as single daily erectile dysfunction therapy. The

Sildenafil citrate comes under class phosphodiesterase type pfizer withdraw an application to the europian medical agency to
5 inhibitors its chemical name 1-[[3-(6,7-dihydro-1-methyl-7- market viagra over the counter for erectile dysfunction that does
oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)-4-ethoxyphenyl] not require any medical supervision, which could delay diagnosis
sulfonyl]-4-methyl piperazine citrate. Its Molecular Formula of possible cardiovascular disease. In the year 2009, Boots has be-
C H N O S. C H O , Its CAS Number 171599-83-0 And there other come the first United Kingdom pharmacy which offer Viagra with-
22 30 6 4 6 8 7
Brands are Revatio, Viagra. Vasodilating agents as a phosphodi- out any need of a prescription. Tesco breaks into the Viagra market
esterase type 5 inhibitor [1]. Sildenafil is an oral drug for erectile and offers the drug to customers without a prescription under a
dysfunction in the market. Drug approval and market development patient group direction. Vardenafil of 10mg is the first phosphodi-
of sildenafil showed as an oral treatment for erectile dysfunction, esterase type 5 inhibitor introduced for erectile dysfunction in an
it is launched by pfizer as brand name of viagra. Then three more orodispersible tablet. In 2012, Avanafil is approved for treatment
phosphodiesterase type 5 inhibitor have been lanced in UK in 1989 of erectile dysfunction by the US Food and Drug Administration in
sildenafil a drug that selectively target and powerfully inhibits the April and by the europian medical agency in June 2013. The United
enzyme phosphodiesterase type 5 inhibitor, is the first synthesized Kingdom patent on Viagra expires opening the way for generic ver-
and tested in pfizer’s UK laboratory. the first trial of sildenafil is sions of sildenafil to be launched. In the year 2014, Manufacturer
treated for coronary heart disease, it is ineffective but penile erec- of Cialis, Lilly, agrees a deal with Sanofi to allow the French firm to
tion is noticed as a side effect. In 2002, tadalafil is approved for the buy exclusive rights to apply and to sell Cialis as a non-prescription
treatment of erectile dysfunction by the europian medical agency medicine in Europe, the United States, and Australia after certain
in November, and by the US food and drug administration in no- patents expire. In recent years the Medicines and Healthcare prod-
vember. In 2003, vardenafil is approved by the europian medical ucts Regulatory Agency recommends sildenafil 50mg should be
agency in March, and by the US food and drug administration in Au- available as a pharmacy medicine, and launches a consultation that
gust. In 2007, the europian commision approved low dose of 2.5mg closes in April [2]. Phosphodiesterase type 5 inhibitor inhibitors

Citation: Lokesh Masagiri., et al. “Brief Review on Sildenafil". Acta Scientific Pharmaceutical Sciences 4.1 (2020): 25-27.